...said FDA issued a complete response letter regarding its NDA seeking final approval of Brixadi buprenorphine...
...is a subcutaneous weekly and monthly extended release formulation of the opioid use disorder therapy buprenorphine...

...in November 2018 against approval of that therapy, which combines samidorphan with partial MOR agonist buprenorphine.Alkermes...

...for substance use disorder; and reSET-O, which is for patients with opioid use disorder receiving buprenorphine...

...its development and distribution costs. Controversy over Orphan exclusivity for opioid use disorder therapy Sublocade buprenorphine...

...recovery pathway, a recent controversy over Orphan exclusivity for an opioid use disorder therapy Sublocade buprenorphine...

...as an adjunct to pharmacotherapy and clinician care for patients with opioid use disorder receiving buprenorphine...

...companies to develop a psychosocial support product intended to enhance the use of Orexo's Zubsolv buprenorphine/naloxone...

...commissioner to lead the development and submission of an NDA, for Probuphine, a long-acting, implantable buprenorphine...

...as an adjunct to pharmacotherapy and clinician care for patients with opioid use disorder receiving buprenorphine...

...yes $1,300 reSET-O Opioid use disorder 84-day cognitive behavior therapy program as adjunct to transmucosal buprenorphine...
...launch. reSET-O was tested in an unblinded, 12-week, 170-patient trial in which patients received supervised buprenorphine...